Researchers are responsible for compliance with applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C
pmc.ncbi.nlm.nih.gov/articles/PMC4508379 Abdulghani AA, Sherr S, Shirin S, et al
Net peptide content tells you how much of the vial weight is actual peptide versus water, salts, and other non-active components
However, Dihexa may not be recommended for patients with certain medical conditions or those who are pregnant or breastfeeding
The CV safety of OW CagriSema in 7000 patients with overweight or obesity and established CV disease will be evaluated in the REDEFINE-3 clinical trial (NCT05669755)
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial